Chloroquine and hydroxychloroquine-related ocular adverse events in SLE treatment: a real-world disproportionality analysis based on FDA adverse event reporting system (FAERS)
The extensive clinical use of HCQ and CQ raises significant concerns regarding their ocular safety profile. This study provides real-world pharmacovigilance evidence supporting a substantial risk of ocular adverse events associated with HCQ/CQ use. Further mechanistic and prospective studies are warranted to elucidate the underlying pathophysiological pathways and to confirm these associations.
Authors
- Si-Qi Zhang (ORCID: https://orcid.org/0000-0003-2818-692X)
- Shi‐Nan Wu (ORCID: https://orcid.org/0000-0002-6992-9059)
- Mengyuan Wang (ORCID: https://orcid.org/0000-0003-2077-361X)
- Kaile Wang (ORCID: https://orcid.org/0000-0003-2249-1026)
- Nuo Dong (ORCID: https://orcid.org/0000-0002-9538-6158)
- Cui-Ting Chen
- Xiang Li (ORCID: https://orcid.org/0009-0005-6470-727X)
Institutions
- Jiangsu University (CN)
- Xiamen University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Xiamen Blood Center (CN)
- Zhenjiang College
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.3389/fphar.2025.1498814
- Citations
- 1
- Primary Topic
- Drug-Induced Ocular Toxicity
- Type
- article
- Field-Weighted Citation Impact
- 1.71